Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$818.93 USD

818.93
5,263,033

-10.81 (-1.30%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $816.25 -2.68 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?

Is (LLY) Outperforming Other Medical Stocks This Year?

5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019

The big drug stocks are on a strong footing of late. Here are five such picks from the biotech and large-cap pharma space that are expected to do well in 2019 too.

Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus

AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.

Lilly Inks Deal With AC Immune for Potential Alzheimer's Drug

Eli Lilly (LLY) signs a deal with AC Immune to jointly develop Morphomer tau aggregation inhibitors, which have the potential to treat Alzheimer's disease (AD) and other neurodegenerative diseases.

Bristol-Myers to Study Opdivo in Combo With Vedanta's VE800

Bristol-Myers (BMY) enters into a collaboration agreement with Vedanta Biosciences to study Opdivo clubbed with the latter's VE800 for treating patients with advanced or metastatic cancers.

The Zacks Analyst Blog Highlights: Eli Lilly, Anthem, BlackRock, CME Group and Southern Company

The Zacks Analyst Blog Highlights: Eli Lilly, Anthem, BlackRock, CME Group and Southern Company

Mallinckrodt (MNK) to Separate Generics & Branded Businesses

Mallinckrodt (MNK) announces plans to split its generic and branded businesses into two different companies.

Mark Vickery headshot

Top Stock Reports for Eli Lilly, Anthem & BlackRock

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly (LLY), Anthem (ANTM) and BlackRock (BLK).

Why Is Lilly (LLY) Up 6.2% Since Last Earnings Report?

Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Eli Lilly (LLY) is a Great Momentum Stock: Should You Buy?

Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.

The Zacks Analyst Blog Highlights: Verizon, Eli Lilly, Accenture, VMware and Schwab

The Zacks Analyst Blog Highlights: Verizon, Eli Lilly, Accenture, VMware and Schwab

Incyte (INCY) Announces Positive Data on Jakafi for GVHD

Incyte (INCY) announces positive data on lead drug Jakafi at the ASH meet for the indication of acute GVHD.

Mark Vickery headshot

Top Stock Reports for Verizon, Eli Lilly & Accenture

Today's Research Daily features new research reports on 16 major stocks, including Verizon (VZ), Eli Lilly (LLY) and Accenture (ACN).

Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know

Eli Lilly (LLY) closed at $118.64 in the latest trading session, marking a +1.4% move from the prior day.

Lilly (LLY) Hits Fresh High: Is There Still Room to Run?

Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Merck (MRK) Receives Approval for 2 HIV Medicines in EU

Merck's (MRK) two new HIV drugs, Pifeltro and Delstrigo, containing doravirine, get approval in EU.

Kinjel Shah headshot

4 Big Pharma Stocks to Add to Your Portfolio in December

The large-cap pharma industry has been on a strong footing lately. Here are four stocks from the space that investors may consider betting on.

Is Eli Lilly and (LLY) Stock Outpacing Its Medical Peers This Year?

Is (LLY) Outperforming Other Medical Stocks This Year?

Zafgen (ZFGN) Plunges as FDA Puts Hold on Diabetes Drug Trial

Zafgen's (ZFGN) stock plunges significantly as the FDA placed a clinical hold on the company's first trial on experimental diabetes drug, ZGN-1061.

4 Reasons Why Lilly is Up More Than 30% This Year So Far

Eli Lilly's (LLY) stock is up 33.7% this year so far. Let us have a look at the reasons for the same.

Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Hot ETF Right Now?

Smart Beta ETF report for FLQL

Corcept Initiates Phase III Study for Cushing's Syndrome

Corcept (CORT) doses first patient in the phase III study of relacorilant for the treatment of Cushing's syndrome.

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

Eli Lilly (LLY) closed at $115.81 in the latest trading session, marking a +1.74% move from the prior day.

Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings

FDA provides updates on Merck (MRK), AstraZeneca (AZN) and Roche (RHHBY) for their cancer drugs. Bayer (BAYRY) reports strong third-quarter results.